View Future GrowthBiotechnology Assets 過去の業績過去 基準チェック /06Biotechnology Assetsは2.8%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで17%毎年増加している。売上は成長しており、年平均1.5%の割合である。主要情報2.80%収益成長率-262.21%EPS成長率Biotechs 業界の成長-7.17%収益成長率1.50%株主資本利益率-27.53%ネット・マージン-55.84%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Jun 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.43m (up 16% from FY 2024). Net loss: €1.92m (loss narrowed 34% from FY 2024).Reported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).Reported Earnings • Nov 02First half 2021 earnings releasedThe company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses.すべての更新を表示Recent updatesReported Earnings • Jun 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.43m (up 16% from FY 2024). Net loss: €1.92m (loss narrowed 34% from FY 2024).お知らせ • Jun 01Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026. Location: gomez acebo & pombo abogados, paseo de la castellana 216, torre realia, madrid., SpainNew Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (€3.1m revenue, or US$3.5m). Market cap is less than US$100m (€17.4m market cap, or US$20.2m).New Risk • Jan 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (6.7% average weekly change). Minor Risks Revenue is less than US$5m (€3.1m revenue, or US$3.6m). Market cap is less than US$100m (€16.3m market cap, or US$19.5m).分析記事 • Dec 05We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • May 19Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid SpainReported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (5.9% average weekly change). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.7m).New Risk • Apr 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.0% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.4m market cap, or US$24.3m).分析記事 • Nov 14We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Nov 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.6m). Market cap is less than US$100m (€23.1m market cap, or US$24.4m).New Risk • Oct 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (4.8% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.0m market cap, or US$20.6m).お知らせ • May 21Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid SpainNew Risk • Apr 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Revenue has declined by 9.9% over the past year. Minor Risks Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.2m). Market cap is less than US$100m (€21.8m market cap, or US$23.4m).New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6.5% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.3m). Market cap is less than US$100m (€22.8m market cap, or US$25.2m).New Risk • Oct 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.1m). Market cap is less than US$100m (€23.7m market cap, or US$25.0m).分析記事 • Apr 19Is Biotechnology Assets (BME:BST) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Nov 17Is ADL Bionatur Solutions (BME:ADL) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Nov 02First half 2021 earnings releasedThe company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses.Is New 90 Day High Low • Feb 08New 90-day high: €0.84The company is up 69% from its price of €0.49 on 10 November 2020. The Spanish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 18New 90-day high: €0.67The company is up 64% from its price of €0.41 on 20 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.収支内訳Biotechnology Assets の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BME:BST 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 253-22030 Sep 253-23030 Jun 253-23031 Mar 253-23031 Dec 243-33030 Sep 243-33030 Jun 243-33031 Mar 244-13031 Dec 23423030 Sep 23423030 Jun 23333031 Mar 23303031 Dec 223-23030 Sep 223-23030 Jun 223-23031 Mar 223-33031 Dec 213-33030 Sep 213-33030 Jun 213-23031 Mar 213-23031 Dec 203-22030 Jun 20-17-2-9031 Mar 20-7-2-2031 Dec 193-34030 Sep 1941-1130030 Jun 1938-1129031 Mar 1931-1428031 Dec 1825-1727030 Sep 1821-1524030 Jun 1816-1420031 Mar 1815-1318031 Dec 1713-1217031 Dec 166-38031 Dec 155-860質の高い収益: BSTは現在利益が出ていません。利益率の向上: BSTは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BSTは利益を出していないが、過去 5 年間で年間2.8%の割合で損失を削減してきた。成長の加速: BSTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: BSTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 7.2% ) と比較することは困難です。株主資本利益率高いROE: BSTは現在利益が出ていないため、自己資本利益率 ( -27.53% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/07 19:16終値2026/06/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biotechnology Assets, S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Pooya HemamiEdison Investment ResearchIñigo Recio PascualGVC Gaesco Valores
Reported Earnings • Jun 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.43m (up 16% from FY 2024). Net loss: €1.92m (loss narrowed 34% from FY 2024).
Reported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).
Reported Earnings • Nov 02First half 2021 earnings releasedThe company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses.
Reported Earnings • Jun 04Full year 2025 earnings releasedFull year 2025 results: Revenue: €3.43m (up 16% from FY 2024). Net loss: €1.92m (loss narrowed 34% from FY 2024).
お知らせ • Jun 01Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026Biotechnology Assets, S.A., Annual General Meeting, Jun 29, 2026. Location: gomez acebo & pombo abogados, paseo de la castellana 216, torre realia, madrid., Spain
New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.9% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (€3.1m revenue, or US$3.5m). Market cap is less than US$100m (€17.4m market cap, or US$20.2m).
New Risk • Jan 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (6.7% average weekly change). Minor Risks Revenue is less than US$5m (€3.1m revenue, or US$3.6m). Market cap is less than US$100m (€16.3m market cap, or US$19.5m).
分析記事 • Dec 05We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • May 19Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain
Reported Earnings • May 19Full year 2024 earnings releasedFull year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023).
New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (5.9% average weekly change). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.7m).
New Risk • Apr 11New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.0% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.4m market cap, or US$24.3m).
分析記事 • Nov 14We Think Biotechnology Assets (BME:BST) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Nov 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.6m). Market cap is less than US$100m (€23.1m market cap, or US$24.4m).
New Risk • Oct 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (4.8% average weekly change). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.0m market cap, or US$20.6m).
お知らせ • May 21Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain
New Risk • Apr 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Revenue has declined by 9.9% over the past year. Minor Risks Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.2m). Market cap is less than US$100m (€21.8m market cap, or US$23.4m).
New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (6.5% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.3m). Market cap is less than US$100m (€22.8m market cap, or US$25.2m).
New Risk • Oct 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.6% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.1m). Market cap is less than US$100m (€23.7m market cap, or US$25.0m).
分析記事 • Apr 19Is Biotechnology Assets (BME:BST) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Nov 17Is ADL Bionatur Solutions (BME:ADL) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Nov 02First half 2021 earnings releasedThe company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses.
Is New 90 Day High Low • Feb 08New 90-day high: €0.84The company is up 69% from its price of €0.49 on 10 November 2020. The Spanish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 18New 90-day high: €0.67The company is up 64% from its price of €0.41 on 20 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period.